Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest treatment of mitral valve disease Stories

2013-10-24 08:34:20

Neovasc's Tiara(TM) Program for the Transcatheter Treatment of Mitral Valve Disease Will Be Featured in Two Sessions VANCOUVER, Oct. 24, 2013 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that researchers will present data on the company's Tiara(TM) transcatheter mitral valve in preclinical development for the treatment of mitral valve disease at the upcoming 25(th) Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the...

2013-05-23 08:27:17

-Longer-Term Animal Data Suggests Tiara Device for the Transcatheter Treatment of Mitral Valve Disease Appears Safe and Well Tolerated TSX Venture Exchange: NVC PARIS and VANCOUVER, May 23, 2013 /CNW/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies to treat vascular disease, reported that positive animal data from its Tiara(TM) program for the transcatheter treatment of mitral valve disease was presented today at EuroPCR 2013, the annual meeting of the European...

2012-10-23 07:28:52

--Researchers Presented Positive Preclinical Data That Set the Stage for Longer-Term Tiara Studies Now Underway and Human Trials Planned for 2013-- --Researchers Also Presented Preliminary Registry Study Results Showing Improved Clinical  Status in Refractory Angina Patients Implanted with Neovasc Reducer(TM)-- TSX Venture Exchange: NVC VANCOUVER, Oct. 23, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that its Tiara(TM) transcatheter mitral valve in...

2012-10-18 07:25:32

--Neovasc's Tiara(TM) Transcatheter Mitral Valve Selected for Inclusion in "Best" New Device Concepts for 2012 Session----Other Presentations Include Tiara Project Update and Neovasc Reducer(TM) Preliminary Registry Results-- TSX Venture Exchange: NVC VANCOUVER, Oct. 18, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that researchers will present data on the company's two major development products at the upcoming 24(th) Annual Transcatheter Cardiovascular...

2012-05-14 02:27:14

--Presentations will Highlight Promising Results from Animal Studies-- TSX Venture Exchange: NVC VANCOUVER, May 14, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies to treat vascular disease, today announced that its Tiara(TM) technology under development for the transcatheter treatment of mitral valve disease will be featured in three scientific sessions at EuroPCR 2012, the annual meeting of the European Association for Percutaneous Cardiovascular...